Compare McKesson Corporation (MCK) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Meta Platforms Inc — how do they compare? McKesson Corporation trades at $824.96 (market cap $97.35B), while Meta Platforms Inc trades at $646.99 (market cap $1.64T). The key difference: Meta Platforms Inc is far larger — about 16.8× McKesson Corporation's market cap, and McKesson Corporation pays the higher dividend (0.39%). Which is the better fit depends on your goals.
| MCK | META | |
|---|---|---|
Market Cap | $97.35B | $1.64T |
Sector | Health | Media |
52-Week High | $995.69 | $790.00 |
52-Week Low | $659.01 | $525.72 |
Enterprise Value | $101.98B | $1.65T |
Dividend Yield | 0.39% | 0.33% |
Volume | — | 24,093,972 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Meta Platforms (META) trades at $646.27, up 0.04% with a bullish technical signal and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $10.44 significantly exceeding expectations of $6.70. Revenue growth remains strong at $201B for 2025, while maintaining impressive profitability with 32.84% net income margin. Recent AI developments including Muse Spark launch and a $21B partnership with CoreWeave highlight continued innovation momentum.
The outlook remains positive with analyst consensus price target of $817.32 representing 26% upside potential. Key opportunities include AI monetization and infrastructure leadership, while risks involve regulatory lawsuits and high capital expenditures. Wall Street sentiment is strongly bullish with 79% buy ratings, though investors should monitor legal challenges and competitive pressures in the evolving AI landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
